The forgotten African root that may quietly be changing how we treat nerve pain

If your feet burn at 2 a.m. when nothing should be touching them — if your sheets feel like sandpaper, or your hands wake you with pins and needles for the third time this week — you already know the conversation this article is having. You have probably tried capsaicin (couldn't stand the burn), lidocaine patches (lasted two hours), the magnesium cream that someone online said would change everything (it did not). Maybe you are on gabapentin or Lyrica and you have learned the trade-off: less nerve pain, but you can no longer drive in the mornings without coffee strong enough to be a problem of its own.

This article is about a plant called devil's claw. The Khoisan of southern Africa have used its root for three hundred years. German pharmacies have sold it since 1981. In the United States, almost no consumer has heard of it — which is unfortunate, because what eighteen months of new research has revealed about devil's claw is the most interesting development in nerve pain in a decade, and it has almost nothing to do with what most people think devil's claw does.

Peripheral neuropathy — the umbrella term for the burning, tingling, and shooting pain in the feet and hands — comes in two flavours. The first is neuropathic: a damaged or compressed nerve sending pain signals it shouldn't be sending. The second, which the International Association for the Study of Pain officially recognised only a few years ago, is called nociplastic pain — pain arising from altered processing in the nervous system itself, where the original nerve damage has long since healed but the inflammatory environment around the nerves has kept the system "stuck" in pain mode. A 2024 paper in the Journal of Clinical Medicine confirmed that most chronic peripheral neuropathy has a significant nociplastic component. The nerve has not gotten worse — the inflammation around it has kept the signal alive. Which is why the gabapentin that worked for the first six months keeps needing a higher dose.

This explains a structural problem with how nerve pain is currently treated in the US. Gabapentin, Lyrica, and the SNRI antidepressants used off-label for neuropathy all work the same way: they quiet the pain signal in the brain. They do not touch the inflammation in the peripheral tissue where the signal is originating. Which is why the side effects feel so disproportionate — you are taking a drug that affects your whole central nervous system to treat a problem that lives in the soft tissue of your feet.

None of the things you have tried for nerve pain are bad — most of them help someone, somewhere, for some length of time. The problem is that almost everything currently sold for peripheral neuropathy targets either the brain (centrally) or the surface of the skin (superficially). The peripheral nerve tissue itself — where the actual inflammation lives — has almost no consumer product aimed at it.

The entire shelf is split between two extremes: drugs that affect your whole brain, or creams that affect only your skin. The tissue in between — where peripheral nerve inflammation actually lives — has no real shelf yet.

There is a word almost no one outside a clinical setting has heard: periarticular. It means the soft tissue around a joint — ligaments, tendon insertions, fascial sheaths, and, critically, the small peripheral nerves running through all of it. When a diabetic patient describes feet that burn at 2 a.m., or hands that go numb gripping a steering wheel, the inflammation driving that pain is not on the skin surface, and it is not in the brain. It is in this periarticular layer — the connective tissue that surrounds the small nerves in your feet, ankles, hands, and wrists.

This is the layer that gets caught in the middle. Centrally-acting drugs like gabapentin act above it, in the brain. Topical surface treatments like lidocaine act above it, on the skin. Almost nothing on the consumer market gets into the periarticular tissue — where the actual inflammation is keeping your nerves sensitised, where the signal that wakes you at 2 a.m. originates. That is the gap. And it is the gap that explains why your current treatment plan keeps escalating without ever actually resolving.

The reason nerve pain "comes back" after each medication adjustment is that the underlying inflammation is being produced by a pathway most US products do not target. It is called 5-LOX — the inflammatory enzyme that produces leukotrienes, the molecules most heavily implicated in the persistent, slow-burning inflammation around chronic nerve tissue. The compound that inhibits 5-LOX most specifically is AKBA, the most active fraction of Boswellia serrata (the resin in frankincense). In January 2024, a paper in the International Journal of Molecular Sciences found that AKBA does more than reduce inflammation — it actively protects spinal cord neurons from inflammatory cell death by activating a cellular pathway called Nrf2-ROS-NLRP3. A 2024 multicentre study across four Italian hospitals then tested AKBA-standardised Boswellia on 103 patients with chronic neuropathic pain whose symptoms had not responded to conventional drugs. After eight weeks, burning, tingling and shooting pain showed clinically meaningful reduction. The study was specifically on patients whose gabapentin-class prescriptions were not working.

The second pathway is even more surprising. The cooling sensation in menthol — which most consumers assume is just a distraction effect — is actually the activation of a specific receptor in sensory nerve endings called TRPM8. A 2022 review in Frontiers in Molecular Neuroscience documented that most of menthol's analgesic activity comes from this receptor, not from the perceived temperature. A clinical proof-of-concept study used 1% menthol cream on cancer patients with chemotherapy-induced peripheral neuropathy — patients whose burning, tingling, and shooting pain had not responded to other options — and found measurable improvement on validated clinical tools. A 2026 paper in Frontiers in Pharmacology went further, confirming that TRPM8 activation interrupts neuropathic pain hypersensitivity through endogenous opioid signaling. The cooling is not the product working on your perception of temperature. It is the product working on your nerves.

The third pathway — the one that ties the picture together — comes from devil's claw itself. Harpagophytum procumbens grows in one place on earth: the sandy edges of the Kalahari, in Namibia and Botswana. The Khoisan have used the dried root for inflammatory conditions and pain for three hundred documented years. Its active compounds — harpagosides — inhibit both COX-2 and TNF-α, two of the most clinically relevant mediators in chronic inflammation. None of that is new. What is new is the direction the research has taken in the last twenty-four months — and it is not about joints.

In May 2024, a paper in the journal Pharmaceuticals reviewed harpagoside's therapeutic potential in neurodegenerative disease and found something most people studying devil's claw had not expected. Beyond its anti-inflammatory activity, harpagoside has neuroprotective properties — it actively shields nerve cells from the kind of inflammatory damage that drives chronic neuropathy. A 2025 paper in PubMed Central went further, demonstrating that harpagoside protects mitochondrial function in neuronal cells under chronic inflammatory stress. In plain language: it does not just dampen the pain signal, it protects the nerve cells themselves from the inflammation that is keeping the signal alive. Pharmaceutical companies are currently spending hundreds of millions developing synthetic compounds that do this. Devil's claw appears to do it as a baseline property of its natural chemistry.

Despite all of this — three hundred years of indigenous use, sixty years of European clinical research, formal inclusion in the European pharmacopoeia since 1981, and now a wave of neuroprotection research — devil's claw is almost completely absent from the American consumer nerve-pain market. The reason is supply chain: the plant cannot be cultivated, every gram comes from wild harvest under CITES export controls, and standardising the extract to a verifiable percentage of harpagosides is technically demanding. Most American formulators source from cheaper, easier ingredients. That gap is starting to close. Google Trends shows US searches for "devil's claw" rising steadily, ahead of any mainstream coverage — many of them landing on Herbavera's site, which is the most-searched US source for the standardised topical extract.

One of the products at the leading edge of that shift is a small American topical called Herbavera Devil's Claw Cream — one of the only US-made nerve-pain creams containing devil's claw at the concentration in the European clinical literature, alongside AKBA-standardised Boswellia (the 5-LOX inhibitor) and TRPM8-activating L-menthol. The difference between a serious formulation and a marketing claim sits in the standardisation percentages, so the spec sheet is below.

Herbavera sells direct to consumers — the manufacturing volume for standardised devil's claw extract is small enough that retail distribution has not been pursued. The brand offers a 90-day money-back guarantee that is, frankly, unusually generous: if the cream does not work for you at any point within ninety days of receiving it, Herbavera will issue a full refund — and they do not require the jar to be returned. You keep the cream. This is a notable risk-shift in a category where most refund policies require the product be returned unopened, which makes the guarantee functionally useless for anyone who actually tried it. Most consumer pain products would not survive 90 days of that kind of refund exposure if they did not work — which is, presumably, why the policy exists.